Fund Times: Doors Closing at Stellar Large-Value Fund
Plus, new offerings from former Citigroup bond star, and more.
Plus, new offerings from former Citigroup bond star, and more.
Allianz NFJ Dividend Value (PNEAX) will close to new investors on April 23, 2007. Since the fund's late-2001 inception, it has outpaced 94% of its large-value rivals. The fund's four-member management team, now headed by founding partner Ben Fischer after former lead manager Cliff Hoover left for Dreman Value Management, has proven adept at finding cheap, dividend-paying stocks. The fund's returns are also helped along by its low expenses.
On the surface, the fund's closing might appear puzzling; after all, the fund focuses mostly on mega-caps and has a manageable $6.4 billion in assets. However, NFJ runs a little more than $20 billion in this strategy overall. While many firms run a lot more than that, we're pleased to see the managers here take early action to slow asset flows. That helps ensure the fund will stay flexible in years to come.
Former Citigroup Manager Plans to Reclaim Old Turf
Stone Harbor Investment Funds, headed by former Citigroup bond manager Peter Wilby, filed to launch two high-yield and emerging-markets bond funds on March 16, 2007. The funds will be managed by Wilby and a number of other highly experienced professionals who left Citigroup Asset Management shortly after the firm sold its asset management business to Legg Mason in late 2005. The managers had considerable success running high-yield funds at Citigroup. Wilby's 10 years at Legg Mason Partners Global High-Yield Bond (formerly called Salomon Brothers High-Yield Bond) made that fund a long-term top performer in the high-yield category, for example.
Evergreen Fills Open Management Slot
Evergreen Investments named Robert Junkin as managing director and lead portfolio manager of Evergreen Health Care on March 19, 2007. Junkin will succeed Walter McCormick, who acted as an interim manager after long-time skipper Liu-Er Chen bolted to rival Delaware Investments in September 2006. Junkin has some big shoes to fill. The fund posted strong returns under Chen, who had medical training and experience in the medical-devices and pharmaceutical industries. Junkin's previous charges included John Hancock Health Sciences and John Hancock Large Cap Equity (TAGRX).
Fund Merger at DWS
DWS plans to merge DWS International Equity into DWS International (SCINX). Shareholders will vote on the consolidation on April 18, 2007. Should the merger garner approval, shareholders in the tiny International Equity will benefit from lower expenses in the surviving fund. It remains to be seen whether they'll also benefit from better returns, however. Manager Matthias Knerr, who runs both funds, is relatively inexperienced.
Goldman Sachs Adds Assets by Acquisition
Pending shareholder approval, Goldman Sachs will merge three Signal funds into existing offerings. Signal Large Cap Growth (SLLAX) will fold into Goldman Sachs Structured Large Cap Growth (GLCGX), Signal Income into Goldman Sachs Core Fixed-Income (GCFIX), and Signal Tax-Exempt Income into Goldman Sachs Municipal Income (GSMIX). Signal shareholders will vote on the three mergers on April 27, 2007. At the very least, the Signal shareholders will be paying less: Each of the three Goldman Sachs funds charges much lower expense ratios.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals
and individual investors. These products and services are usually sold through
license agreements or subscriptions. Our investment management business generates
asset-based fees, which are calculated as a percentage of assets under management.
We also sell both admissions and sponsorship packages for our investment conferences
and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.